|
1
|
Pedersen BK: Anti-inflammatory effects of
exercise: Role in diabetes and cardiovascular disease. Eur J Clin
Invest. 47:600–611. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Welborn TA, Garcia-Webb P, Bonser A,
McCann V and Constable I: Clinical criteria that reflect C-peptide
status in idiopathic diabetes. Diabetes Care. 6:315–316. 1983.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Song Y, Huang L and Yu J: Effects of
blueberry anthocyanins on retinal oxidative stress and inflammation
in diabetes through Nrf2/HO-1 signaling. J Neuroimmunol. 301:1–6.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
NCD Risk Factor Collaboration (NCD-RisC):
Worldwide trends in diabetes since 1980: A pooled analysis of 751
population-based studies with 4.4 million participants. Lancet.
387:1513–1530. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Liu Q, Zhang F, Zhang X, Cheng R, Ma JX,
Yi J and Li J: Fenofibrate ameliorates diabetic retinopathy by
modulating Nrf2 signaling and NLRP3 inflammasome activation. Mol
Cell Biochem. Dec 21–2017.(Epub ahead of print).
|
|
6
|
Keech AC, Mitchell P, Summanen PA, O'Day
J, Davis TM, Moffitt MS, Taskinen MR, Simes RJ, Tse D, Williamson
E, et al FIELD study investigators, : Effect of fenofibrate on the
need for laser treatment for diabetic retinopathy (FIELD study): A
randomised controlled trial. Lancet. 370:1687–1697. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Henshaw FR, Boughton P, Lo L, McLennan SV
and Twigg SM: Topically applied connective tissue growth
factor/CCN2 improves diabetic preclinical cutaneous wound healing:
Potential role for CTGF in human diabetic foot ulcer healing. J
Diabetes Res. 2015:2362382015. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Liu F, Tang W, Chen D, Li M, Gao Y, Zheng
H and Chen S: Expression of TGF-β1 and CTGF is associated with
fibrosis of denervated sternocleidomastoid muscles in mice. Tohoku
J Exp Med. 238:49–56. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Montford JR and Furgeson SB: A new CTGF
target in renal fibrosis. Kidney Int. 92:784–786. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Klaassen I, van Geest RJ, Kuiper EJ, van
Noorden CJ and Schlingemann RO: The role of CTGF in diabetic
retinopathy. Exp Eye Res. 133:37–48. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Zhang H, Cai X, Yi B, Huang J, Wang J and
Sun J: Correlation of CTGF gene promoter methylation with CTGF
expression in type 2 diabetes mellitus with or without nephropathy.
Mol Med Rep. 9:2138–2144. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Liu J, Wang L, Tian XY, Liu L, Wong WT,
Zhang Y, Han QB, Ho HM, Wang N, Wong SL, et al: Unconjugated
bilirubin mediates heme oxygenase-1-induced vascular benefits in
diabetic mice. Diabetes. 64:1564–1575. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Chen YC, Chen BC, Yu CC, Lin SH and Lin
CH: miR-19a, −19b, and −26b mediate CTGF expression and pulmonary
fibroblast differentiation. J Cell Physiol. 231:2236–2248. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Zinman B, Lachin JM and Inzucchi SE:
Empagliflozin, cardiovascular outcomes, and mortality in type 2
diabetes. N Engl J Med. 374:10942016.PubMed/NCBI
|
|
16
|
Pothineni NV and Mehta JL: Follow-up of
glycemic control and cardiovascular outcomes in type 2 diabetes. N
Engl J Med. 373:977–978. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Piette JD, Heisler M and Wagner TH:
Problems paying out-of-pocket medication costs among older adults
with diabetes. Diabetes Care. 27:384–391. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Wang J, Duan L, Guo T, Gao Y, Tian L, Liu
J, Wang S and Yang J: Downregulation of miR-30c promotes renal
fibrosis by target CTGF in diabetic nephropathy. J Diabetes
Complications. 30:406–414. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Zhu L, Zhao S, Liu S, Liu Q, Li F and Hao
J: PTEN regulates renal extracellular matrix deposit via increased
CTGF in diabetes mellitus. J Cell Biochem. 117:1187–1198. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Negi G, Nakkina V, Kamble P and Sharma SS:
Heme oxygenase-1, a novel target for the treatment of diabetic
complications: Focus on diabetic peripheral neuropathy. Pharmacol
Res. 102:158–167. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Baelde HJ, Eikmans M, Lappin DW, Doran PP,
Hohenadel D, Brinkkoetter PT, van der Woude FJ, Waldherr R,
Rabelink TJ, de Heer E, et al: Reduction of VEGF-A and CTGF
expression in diabetic nephropathy is associated with podocyte
loss. Kidney Int. 71:637–645. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Sun J, Zheng H, Qin X and Qi L: Effects of
immunocytokine combined with cattle encephalon glycoside and
ignotin on CTGF, HO-1 and NT-3 in patients with type 2 diabetic
peripheral neuropathy. Iran J Public Health. 46:1632–1638.
2017.PubMed/NCBI
|
